Alpha‐Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma ( PDAC ): A Case Report
Cancer Reports · 2026
DOI: 10.1002/cnr2.70547 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Kaiwen Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, the Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Biomarkers, Tumor, alpha-Fetoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Research Foundation, Guangdong Medical Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, with high rates of mortality and drug resistance. Carbohydrate antigen 19‐9 (CA19‐9) is a tumor biomarker for diagnosis and prognosis in PDAC. However, elevated alpha‐fetoprotein (AFP) is exceedingly rare in the PDAC patient. Case Presentation Herein, we describe a 67‐year‐old woman who presented with elevated AFP before the diagnosis of PDAC. In March 2025, this patient who had elevated AFP and CA19‐9 levels and was presenting with jaundice, was diagnosed with PDAC. Subsequently, she underwent pancreaticoduodenectomy, partial resection of the superior mesenteric vein (SMV), and SMV reconstruction. After radical resection (R0), the levels of AFP and CA19‐9 were significantly decreased. Next, she was treated with adjuvant chemotherapy (gemcitabine plus capecitabine). After four cycles of treatment, the patient presented with diarrhea, weight loss, poor nutritional status, and other signs of poor tolerance to chemotherapy. Thus, the regimen was changed to pembrolizumab plus trametinib. Hepatic recurrence was detected at the 7‐month follow‐up. At 11 months after surgery, the patient developed a biliary tract infection and obstructive jaundice, and ultimately died.
Conclusions
This case demonstrates that AFP may be a potential biomarker for PDAC, especially in the CA19‐9‐negative PDAC patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, the Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
- Pathological Diagnosis Center, the Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
- Department of Hepatobiliary and Pancreatic Surgery, the Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
ORCID-Profile: Kaiwen Zhong, Xiaoying Wu, Xiangling Lin, Maoyun Xie, Min Deng, Qiang Tao, Wei Qin, Songlin Peng
Förderung
- Shenzhen Research Foundation
- Guangdong Medical Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen Postdoctoral Research Fund
Zitieren
APA
Zhong, K., Wu, X., Lin, X., Xie, M., Deng, M., Tao, Q., Qin, W., & Peng, S. (2026). Alpha‐Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma ( PDAC ): A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70547
Vancouver
Zhong K, Wu X, Lin X, Xie M, Deng M, Tao Q, et al. Alpha‐Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma ( PDAC ): A Case Report. Cancer Reports. 2026. doi:10.1002/cnr2.70547
BibTeX
@article{Zhong2026,
author = {Zhong, Kaiwen and Wu, Xiaoying and Lin, Xiangling and Xie, Maoyun and Deng, Min and Tao, Qiang and Qin, Wei and Peng, Songlin},
title = {Alpha‐Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma ( PDAC ): A Case Report},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70547}
}
EUVIMED